Biosecurity

The introduction of the BIOSECURE Act marks a significant moment in U.S. legislative history, specifically targeting the intersection of national security and biotechnology. This proposed legislation aims to halt federal contracts with Chinese biotech firms, citing potential national security

The proposed BIOSECURE Act stands poised to significantly alter the landscape of U.S.-China biopharma partnerships by addressing national security concerns through restrictive measures. Specifically, the act aims to block certain Chinese biotech equipment and service providers from the U.S. market.

Recent actions by U.S. House lawmakers have cast a spotlight on GenScript, a Chinese Contract Development and Manufacturing Organization (CDMO), and its cell therapy division, Legend Biotech, amidst concerns of potential Chinese Communist Party (CCP) influence within the American biotech realm.

Within the dynamic landscape of the Contract Development and Manufacturing Organization (CDMO) industry, strategic alliances are becoming increasingly crucial. The latest collaboration between Japan's AGC Biologics and the Netherlands-based BioConnection illustrates this point poignantly. They

The biotechnology sector could be on the brink of a substantial change as legislative gears turn with the possibility of the BIOSECURE Act being widened to encompass drug developers. This pivot towards inclusive scrutiny, primarily targeting relationships with Chinese biopharma entities, sparks a

Navigating Regulatory Expectations Proactive Measures for Compliance Novartis is adjusting its Chinese partnerships due to a proposed U.S. bill, the BIOSECURE Act, aimed at foreign biotech firms with potential security risks. While the act isn't law yet, Novartis is taking preemptive action to